The prostate glycoproteome can undergo a wide range of different alterations during the occurrence and progression of prostate cancer, which might explain some of the interpatient heterogeneity in disease severity and outcomes. In this Review, the authors describe the potential for alterations in the glycoproteome to provide biomarkers and/or clinical targets for the prognosis and/or treatment of prostate cancer.
- Jennifer Munkley
- Ian G. Mills
- David J. Elliott
